at 001

Anti-VEGFR2/KDR/CD309 Antibody (AT001) is a human antibody expressed in CHO cells, specifically targeting VEGFR2/KDR/CD309. It features a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. For an isotype control, refer to HumanIgG4kappa, Isotype Control.

Aldose reductase-IN-1 (AT-001, Caficrestat) is a highly potent inhibitor of aldose reductase with an IC50 value of 28.9 pM, which can target the relaxin hormone signaling pathway in prostate cancer models.

DJ001 is a highly specific, selective, and non-competitive protein tyrosine phosphatase σ (PTPσ) inhibitor with an IC50 of 1.43 μM, and it promotes the regeneration of hematopoietic stem cells.

NB001 (HTS 09836) is an adenyl cyclase 1 inhibitor that affects both neural and non-neural pain.

APX001 is a prodrug of APX-001A. APX001 is the first-in-class inhibitor of the fungal protein Gwt1.

AKP-001 is a selective inhibitor of MAPK of the p38α isoform and is used in the study of immune and digestive disorders.

FT001 is a potent, selective and orally available inhibitor of BET Bromodomain with antitumor activity. FT001 inhibited the expression of MYC with the IC50 value of 0.46 μM). FT001 has potent antiproliferative effects against MV-4-11 and demonstrates significant MYC mRNA suppression both in vitro and in vivo.

AKI-001 is a potent Aurora kinase inhibitor, which exhibits low nanomolar potency against both Aurora A and Aurora B enzymes, excellent cellular potency (IC50 < 100 nM), and good oral bioavailability. Phenotypic cellular assays show that both Aurora A and Aurora B are inhibited at inhibitor concentrations sufficient to block proliferation. Importantly, the cellular activity translates to potent inhibition of tumor growth in vivo. An oral dose of 5 mg/kg QD is well tolerated and results in near stasis (92% TGI) in an HCT116 mouse xenograft model.

LIT-001 free base improves social interaction in a mouse model of autism. LIT-001 free base is the first nonpeptide oxytocin receptor (OT-R) agonist (EC50=55 nM; Ki=226 nM).

LIT-001 improves social interaction in a mouse model of autism.It is the first nonpeptide oxytocin receptor agonist with EC50 of 55 nM and Ki of 226 nM.

RP-001 is a selective agonist of picomolar short-acting S1P1 (EDG1)(EC50 of 9 pM), has little activity on S1P2-S1P4 and only moderate affinity for S1P5.

RP-001 hydrochloride is a selective agonist of picomolar short-acting S1P1 (EDG1)(EC50 of 9 pM), has little activity on S1P2-S1P4 and only moderate affinity for S1P5.

Compound N001-0004 is a useful organic compound for research related to life sciences and the catalog number is T131388.

GA001 is a potent G9a antagonist with an IC50 of 1.32 μM. It can induce autophagy and apoptosis, and is applicable in the treatment of breast cancer.

HYL001 (compound 338) is a potent inhibitor of the TGFβ receptor 1 (ALK5), exhibiting approximately nine times the efficacy of its structurally related counterpart, galunisertib, in eliminating liver metastasis tumors generated in mice.

AM-001 is a non-competitive inhibitor of Epac1, preventing the activation of its downstream effector Rap1 in cultured cells. This compound is utilized in research related to cardiac diseases.

ETD001 is a long-acting ENaC inhibitor with an IC50 value of 57.5 nM in HBE cells. It is applicable for research in cystic fibrosis.

HL001 is an orally active small molecule inhibitor of cyclophilin A (CypA) and a receptor antagonist of lysophosphatidic acid 1 (LPA1). It induces cell cycle arrest and apoptosis in tumor cells via p53. By downregulating G3BP1, HL001 promotes reactive oxygen species production and DNA damage to stabilize p53. It disrupts the interaction between MDM2 and p53-72R in a CypA-dependent manner. HL001 exhibits antitumor activity and can also be used in research on pulmonary fibrosis.

IDB-001 is an inhibitor of the ribosomal PTC that selectively represses protein synthesis by sequence. It inhibits the viability of HCC-1143 cells with an EC50 of 0.84 μM and also hinders the viability of MYC-dependent cancer cells.

STG-001 is an antagonist of retinol-binding protein 4 (RBP4). By inhibiting RBP4, STG-001 reduces the synthesis of retinaldehyde and bis-retinoids, thereby preventing photoreceptor degeneration. This compound is applicable in studies related to sex-linked hereditary retinopathies such as Stargardt disease (STGD).

STL001 is a potent and selective inhibitor of FOXM1. It triggers the translocation of nuclear FOXM1 to the cytoplasm, promoting autophagic degradation. STL001 enhances the sensitivity of human cancers to broad-spectrum cancer therapies.

CVI-LM001 is an inhibitor of PCSK9 that regulates blood levels of low-density lipoprotein cholesterol (LDL-C) by preventing the interaction between PCSK9 and low-density lipoprotein receptors (LDLR), thereby exerting a lipid-lowering effect.

AH001 is an orally active compound that binds to a concealed pocket near GDP within RhoA, exhibiting a binding affinity of 73.16 nM. By interacting with GDP, AH001 stabilizes the interaction between RhoA and its endogenous inhibitor, RhoGDIα. This compound reduces nuclear translocation of downstream MRTFA and downregulates fibrosis/hypertrophy-related proteins. AH001 alleviates myocardial remodeling in various heart failure animal models and 3D cardiac tissue models. Its cardioprotective effects are mediated through the RhoA-RhoGDIα axis, effectively inhibiting downstream RhoA activation signals.

MRC-G-001 is a Genipin derivative with an IC50 value of 117 μM against A549 cancer cells. It inhibits the phosphorylation of EGFR, JAK1, and STAT3, and modulates the expression of proteins related to epithelial-mesenchymal transition (EMT), thereby suppressing cell migration and invasion. MRC-G-001 induces cell cycle arrest and apoptosis (apoptosis) and is applicable in studies of cancers, including non-small cell lung cancer.